Biotie/Lundbeck report results of Phase III studies for Selincro for Alcohol Dependence

Biotie announced that its partner H. Lundbeck A/S has presented results from the Phase III program of Selincro (nalmefene), an investigational compound for the treatment of Alcohol Dependence, at the 20th European Congress of Psychiatry (EPA) in Prague, Czech Republic. Data from the three placebo-controlled phase III studies (ESENSE 1, ESENSE 2 and SENSE) was discussed during the symposium. In addition, the ESENSE 1 study was presented as a poster by Prof. Dr. Karl Mann et al. Further details of the ESENSE 2 and SENSE studies will be presented at the Annual Research Society on Alcoholism (RSA) Scientific Meeting in San Francisco in June 2012.